Dialysis pioneer Invizius named ‘Best Innovative MedTech’
- On October 23, 2018
- By GrowthInvest Admin
Invizius CEO Richard Boyd, receives his award, photographed with OBN CEO John Harris, Sue Staunton, Head of Technology at award sponsor James Cowper Kreston, and science communicator and event host Sally Le Page.
Invizius, a University of Edinburgh spinout whose technology promises to improve the lives of millions of dialysis patients, has been named Best Innovative MedTech company at the prestigious OBN Awards.
The company’s success in the awards, which have a high profile in the life sciences sector, follows on from a seed investment of £500,000 from Mercia Fund Managers in May 2018.
Invizius’ H-Guard™ product acts as a primer that ‘hides’ the blood filter used in dialysis from the body’s immune system. This has the potential to greatly cut the risks of cardiovascular disease, which severely reduces life expectancy among long-term dialysis patients.
Richard Boyd, Chief Executive Officer of Invizius, said: “The team is enormously proud that our innovation has been recognised with this prestigious award. The company is on an exciting journey and this adds to our momentum.”
GET IN TOUCH!
CALL US020 7071 3945
FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.